Cargando…

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.

Detalles Bibliográficos
Autores principales:	Kuzmina, Elena, Lomaia, Elza, Morozova, Elena, Chelysheva, Ekaterina, Shukhov, Oleg, Petrova, Anna, Chitanava, Tamara, Vlasova, Yulia, Sbityakova, Evgenia, Makarova, Tayana, Nemchenko, Irina, Bykova, Anastasiya, Gurianova, Margarita, Kohno, Alina, Turkina, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429403/ http://dx.doi.org/10.1097/01.HS9.0000969596.20821.8c

Ejemplares similares

P677: THE FACTORS OF LATE MOLECULAR RELAPSES AFTER TYROSINE KINASE INHIBITORS DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
por: Petrova, Anna, et al.
Publicado: (2023)

P682: THE RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
por: Gurianova, Margarita, et al.
Publicado: (2023)

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

Poster: CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina Yu., et al.
Publicado: (2021)

Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina Yu., et al.
Publicado: (2021)

P655: LIMITATIONS OF USING CD26+ LEUKEMIA STEM CELL QUANTITATION IN CML PATIENTS TO ASSESS RESIDUAL LEUKEMIA CLONE
por: Kapranov, Nikolay, et al.
Publicado: (2023)

PB1970: LONG-TERM RESULTS OF THERAPY FOR CHRONIC MYELOID LEUKEMIA: A 20-YEAR ANALYSIS OF THE GIPAP PROGRAM IN RUSSIA
por: Shukhov, Oleg, et al.
Publicado: (2023)

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience
por: Chitanava, Tamara, et al.
Publicado: (2023)

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
por: Mauro, Michael J., et al.
Publicado: (2023)

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients
por: Lavrov, Alexander V., et al.
Publicado: (2019)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
por: Čuřík, Nikola, et al.
Publicado: (2023)

T315I(+) tyrosine-kinase independent CML cells resistance
por: Nicolini, Franck Emmanuel, et al.
Publicado: (2017)

P1063: A SINGLE CENTER EXPERIENCE OF DIAGNOSTICS AND TREATMENT OF RARE MYELOID/LYMPHOID NEOPLASMS WITH PDGFRB GENE REARRANGEMENT
por: Nemchenko, Irina, et al.
Publicado: (2023)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
por: Tomassetti, Sarah, et al.
Publicado: (2022)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
por: Breccia, Massimo, et al.
Publicado: (2023)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
por: Yuda, Junichiro, et al.
Publicado: (2022)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB
por: Cortes, Jorge, et al.
Publicado: (2023)

Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia
por: Lavrov, Alexander V., et al.
Publicado: (2016)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

FRI673 REMS Technology For The Evaluation Of BMD In Hypothyroidism
por: Lombardi, Fiorella Anna, et al.
Publicado: (2023)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
por: Morozova, E.V., et al.
Publicado: (2015)

An interesting case of chronic myeloid leukemia (CML) with T315I mutation raising suspicion of de novo AML, a diagnostic conundrum
por: Iqbal, Phool, et al.
Publicado: (2023)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

PT673. Pharmacological analysis of nicotine-induced tremor
por: Kunisawa, Naofumi, et al.
Publicado: (2016)

THU673 Unusual Metastasis Of Differentiated Thyroid Carcinoma
por: Aiad, Mina, et al.
Publicado: (2023)

Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
por: Zhou, Lu, et al.
Publicado: (2019)

Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017)

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
por: Padala, Sandeep, et al.
Publicado: (2023)

Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia
por: Lavrov, Alexander V., et al.
Publicado: (2017)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hijiya, N., et al.
Publicado: (2022)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Asciminib Mitigates DNA Damage Stress Signaling Induced by Cyclophosphamide in the Ovary
por: Mattiello, Luca, et al.
Publicado: (2021)

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
por: Choi, Eun-Ji
Publicado: (2023)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
por: Hughes, Timothy, et al.
Publicado: (2023)

The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL
por: Ru, Yi, et al.
Publicado: (2016)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cdpovla171tu1jvo9bkhstvmin